![]()
- Governments Must Act to Avoid More Dubais: El-Erian
- Regulators Compile Global List of 'Systemic Risk' Banks
- Dubai Stocks Shed 7%, Abu Dhabi Tumbles 8%
- The World's Biggest Debtor Nations
- UAE, Abu Dhabi Ratings Unlikely to Be Cut: Moody's
- US Midwest Business Expands Stronger Than Expected
- BofA Aims to Clearly Spell Out Credit Card Terms
- Advertisers Sticking With Tiger After Accident
- What Black Friday Shoppers Spent on – And Where
- Buy or Hold: Analyst Rates 10 Retail Stocks
- Execs: Tis The Season To Take Control
- November Winners & Losers
- Farrell: Testing Those International Waters Again
- Bob Doll: “We Continue to See Gains”
- My Commodities Outlook after Dubai: Dennis Gartman
- Saab Lovers Sound Off
- Tiger Ads Continue To Run Today
- Cheap Gas, Cheap Gifts
MOST SHARED
- Dubai Stocks Shed 7%, Abu Dhabi Tumbles 8%
- Tiger Woods Wants to Protect Family Privacy: Agent
- South Korea Sees Exports Bouncing, but Risks Remain
- US Senator Opposes Fed Chief Bernanke Renomination
- Governments Must Take Steps To Avoid More Dubais: El-Erian
- Dubai's Nakheel Seeks Suspension $5.25 Billion in Bonds
- Tiger Ads Continue To Run Today
- Dubai is Harsh Reminder of Prolonged Global Recovery
- Japan Won't Intervene to Weaken Yen: Finance Minister
- Tamminen: Copenhagen And Beyond
Fast-selling cancer drugs boosted first-quarter sales at Roche Holding by 16% to 11.4 billion Swiss francs ($9.41 billion), the Swiss drugmaker said, raising its outlook for the full year.
Sales in its all-important pharmaceutical division rose by 18% to 9.14 billion francs, the world's largest maker of cancer drugs said on Wednesday, driven by new uses of its top cancer treatments Avastin, Herceptin, Xeloda and MabThera.
"Based on the successful first three months we raise the outlook for 2007 and expect core earnings per share to grow above group sales," Chief Executive Officer Franz Humer said in a statement.
The group had previously said core earnings per share would grow in line with sales. The company left its sales outlook for 2007 unchanged, forecasting double-digit growth for group and pharma sales in 2007, above market sales growth.
Roche certificates, its most commonly traded form of equity, have lost 6% since its full-year results on worries over earlier cautious 2007 guidance and future margin growth at the company, which trades at a premium compared to the sector.
The first-quarter numbers were just above the average expectations in a Reuters poll of 20 analysts. These were for group sales to rise to 11.12 billion francs, while pharma sales were pencilled in at 8.9 billion.
Sales of Roche's Tamiflu flu drug were boosted by further stockpiling by governments, as countries across the world brace themselves for a possible outbreak of a bird flu pandemic.
Roche also gave a positive outlook for its Actemra arthritis drug, one of the most promising drugs in its product pipeline, saying first Phase III trials had shown positive results.
In a separate statement, Roche also said its cancer drug Avastin had been approved in Japan for patients with inoperable advanced or recurrent colorectal cancer.
Roche has a strong portfolio of new drugs to fight cancer, the fastest-growing area of medical advances, substantial exposure to profitable biotech therapies and few generic challenges in the coming years.
Roche shares trade at around 20 times expected 2007 earnings, well above those of its rivals Novartis at 17 times and GlaxoSmithKline at 15 times, which some analysts say may limit the stock's upside potential.
- Ever wished your cab driver would stop chatting and just get to where you're going? Well, that moment is closer than ever.
- With Americans cutting back on spending, holiday tipping will take another hit this year.
- From the why-didn’t-I-think-of-that file, we present Jason Sadler, a man whose job is wearing T-shirts.
- Shopping for a gadget hound? The choices can be baffling. Here are a few that should be a hit.
- "The Who" will be the halftime act for Super Bowl XLIV on Feb. 7 in Miami. Is the NFL behind the times?
- Zhu Zhu Pets are this year's must-have toy, fetching $40 or more on eBay.












